Ostia Sciences Inc.
| Private | |
| ISIN | 🆔 |
| Industry | Biotechnology |
| Founded 📆 | 2019 |
| Founders 👔 | Dr. Abdelahhad Barbour (CEO and Co-founder) [1] and Michael Glogauer (CSO and Co-founder) [1] |
| Headquarters 🏙️ | , Toronto, Ontario , Canada |
Area served 🗺️ | |
| Products 📟 | Microbiome therapeutics; oral probiotics |
| Members | |
Number of employees | |
| 🌐 Website | ostiasciences |
| 📇 Address | |
| 📞 telephone | |
Ostia Sciences Inc. is a Canadian biotechnology company developing microbiome-based therapeutics for oral health.[2] The company focuses on bacteriocin and lantibiotic-producing bacterial strains, including the investigational oral probiotic candidate SALI-10. [3] Founded in 2019, the company focuses on developing targeted probiotics and lantibiotics intended to address oral diseases while maintaining oral microbial balance. [3]
History
Ostia Sciences was founded in Toronto, Canada, to translate oral microbiome research into clinical products for prevention and supportive care in dentistry and medicine.[2]
In 2025, Ostia Sciences announced a manufacturing collaboration with Expert’Biome CDMO by Lallemand to support process development and clinical-grade production for an oral care probiotic program.[3]
Research and technology
Ostia Sciences’s research is centered on the oral microbiome, particularly bacteriocins and phosphorylated lantibiotics that exhibit narrow-spectrum activity against oral and respiratory pathogens while sparing beneficial taxa. [4] The company applies metagenomics, bioinformatics, and flow cytometry to investigate host–microbe interactions and identify strain-level features associated with disease. [4]
Peer-reviewed research cited by the company includes studies of their discovered phosphorylated lantibiotics and oral community defense mechanisms published in PNAS.[4] Ostia-affiliated clinicians have also reported changes in oral innate immunity during head and neck cancer therapy, including decreased oral neutrophil counts and altered commensal balance following radiation, in the International Journal of Molecular Sciences.[5]
Products and pipeline
- SALI-10 – a Streptococcus salivarius–based probiotic that produces targeted phosphorylated lantibiotics designed to inhibit disease-associated bacteria (e.g., opportunistic pathogens) while supporting oral commensals.[4]
Public engagement
Ostia communicates research developments through conference presentations and media. In 2025, company representatives discussed oral microbiome science and probiotic development on the NutraCast podcast by NutraIngredients-USA.[6]
See also
- Oral microbiology
- Microbiome
- Probiotic
- Bacteriocins
References
- ↑ 1.0 1.1 "U of T start-up's breakthrough molecule: Eliminating pathogens without harming oral microbiota". University of Toronto.
- ↑ 2.0 2.1 "Ostia Sciences Inc. Completes $1.46M Seed Round to Develop Microbiome Therapeutics Platform". Business Wire. 18 July 2025.
- ↑ 3.0 3.1 3.2 "Ostia Sciences and Expert'Biome CDMO by Lallemand celebrate a major milestone for producing a new oral care probiotic". Lallemand Health Solutions. 2025.
- ↑ 4.0 4.1 4.2 4.3 Barbour, Abdelahhad (2023). "Discovery of phosphorylated lantibiotics with proimmune activity that regulate the oral microbiome". PNAS. 120 (22). Bibcode:2023PNAS..12019392B. doi:10.1073/pnas.2219392120. PMC 10235938 Check
|pmc=value (help). PMID 37216534 Check|pmid=value (help). Unknown parameter|article-number=ignored (help) - ↑ Mojdami (2022). "Oral Neutrophils and Microbiome Changes During Head and Neck Cancer Treatment". International Journal of Molecular Sciences. 23 (18): 9594. doi:10.3390/ijms23179594. PMC 9456060 Check
|pmc=value (help). PMID 36076990 Check|pmid=value (help). - ↑ "NutraCast: The new probiotic that could reshape oral health as we know it". NutraIngredients-USA. 11 July 2025.
External links
This article "Ostia Sciences" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Ostia Sciences. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
